Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07446335) titled 'A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital of Zhengzhou University
Condition:
Advanced Esophageal Squamous Cell Carcinoma
Intervention:
Drug: anlotinib combined with benmelstobart
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: April 2026
Target Sample Size: 578
Countri...